866-997-4948(US-Canada Toll Free)

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Oncology

No. of Pages : 321 Pages


Global Markets Directs, \'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL). Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Chronic Lymphocytic Leukemia (CLL).
  • A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Chronic Lymphocytic Leukemia (CLL) Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Chronic Lymphocytic Leukemia (CLL) 12
Chronic Lymphocytic Leukemia (CLL) Therapeutics under Development by Companies 14
Chronic Lymphocytic Leukemia (CLL) Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 22
Comparative Analysis 22
Mid Clinical Stage Products 23
Comparative Analysis 23
Early Clinical Stage Products 24
Comparative Analysis 24
Discovery and Pre-Clinical Stage Products 25
Comparative Analysis 25
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Products under Development by Companies 26
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Products under Investigation by Universities/Institutes 31
Companies Involved in Chronic Lymphocytic Leukemia (CLL) Therapeutics Development 32
Bristol-Myers Squibb Company 32
F. Hoffmann-La Roche Ltd. 33
Amgen Inc. 34
Sanofi-Aventis 35
Viralytics Ltd. 36
GlaxoSmithKline plc 37
Genentech, Inc. 38
MedImmune LLC 39
Gilead Sciences, Inc. 40
Daiichi Sankyo Company, Ltd 41
Merck & Co., Inc. 42
Emergent BioSolutions Inc. 43
Lentigen Corporation 44
Infinity Pharmaceuticals, Inc. 45
Amorfix Life Sciences Ltd. 46
Celltrion, Inc. 47
Novartis AG 48
Astellas Pharma Inc. 49
Gedeon Richter Plc. 50
ImmunoGen, Inc. 51
SuperGen, Inc. 52
Genmab A/S 53
Cyclacel Pharmaceuticals Inc. 54
Celgene Corporation 55
Onyx Pharmaceuticals, Inc. 56
Bayer AG 57
Incyte Corporation 58
Merck KGaA 59
4SC AG 60
IMMUNOMEDICS, INC 61
MethylGene Inc 62
Portola Pharmaceuticals, Inc. 63
Mundipharma International Limited 64
MorphoSys AG 65
Panacea Biotec Limited 66
Simcere Pharmaceutical Group 67
Hybrigenics S.A. 68
Spectrum Pharmaceuticals, Inc. 69
Memgen, LLC. 70
Hutchison MediPharma Limited 71
Arno Therapeutics, Inc. 72
Semafore Pharmaceuticals, Inc. 73
Ferrer Internacional S.A. 74
Onconova Therapeutics, Inc 75
Tragara Pharmaceuticals, Inc. 76
KaloBios Pharmaceuticals, Inc. 77
Aprea AB. 78
Cylene Pharmaceuticals, Inc. 79
Biothera 80
Profectus BioSciences, Inc. 81
LFB Biotechnologies, S.A.S.U. 82
KAEL-GemVax 83
Bio Sidus S.A. 84
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 85
Assessment by Monotherapy Products 85
Assessment by Combination Products 86
Assessment by Route of Administration 87
Assessment by Molecule Type 89
Drug Profiles 92
bendamustine hydrochloride - Drug Profile 92
obinutuzumab - Drug Profile 94
obinutuzumab - Drug Profile 96
sorafenib tosylate - Drug Profile 98
niraparib - Drug Profile 102
mocetinostat - Drug Profile 104
SAR-245409 - Drug Profile 107
4SC-202 - Drug Profile 109
AT-7519 - Drug Profile 111
AR-42 - Drug Profile 113
carfilzomib - Drug Profile 115
TRU-016 - Drug Profile 118
TG-02 - Drug Profile 120
forodesine hydrochloride - Drug Profile 121
bendamustine hydrochloride - Drug Profile 123
idelalisib - Drug Profile 124
ISF-35 - Drug Profile 126
tertomotide - Drug Profile 128
sapacitabine - Drug Profile 130
SF-1126 - Drug Profile 132
rigosertib sodium - Drug Profile 134
LG-768 - Drug Profile 137
AVL-291 - Drug Profile 138
KB-004 - Drug Profile 139
BMS-936564 - Drug Profile 141
GM-K562 Cell Vaccine - Drug Profile 142
dinaciclib - Drug Profile 144
CST-103 - Drug Profile 146
CVA-21 - Drug Profile 147
MOR-208 - Drug Profile 151
MEDI-551 - Drug Profile 152
DI-B4 - Drug Profile 154
8-chloroadenosine - Drug Profile 155
IMMU-114 - Drug Profile 156
ciclopirox olamine - Drug Profile 157
PRT-2607 - Drug Profile 158
silmitasertib - Drug Profile 159
CTL-019 - Drug Profile 161
exatecan mesylate - Drug Profile 163
Kappa CD28 T Cells - Drug Profile 165
marizomib - Drug Profile 166
ofatumumab - Drug Profile 168
CD19CAR PBTLs + EBV-CTLs - Drug Profile 172
afuresertib - Drug Profile 173
ublituximab - Drug Profile 175
bevacizumab - Drug Profile 177
plerixafor - Drug Profile 181
ocaratuzumab - Drug Profile 183
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 185
inecalcitol - Drug Profile 187
duvelisib - Drug Profile 189
CD4 Donor Lymphocytes - Drug Profile 191
rituximab biosimilar - Drug Profile 192
Vivia-007 - Drug Profile 194
Vivia-008 - Drug Profile 195
RG-7593 - Drug Profile 196
Vivia-1615 - Drug Profile 198
Vivia-577 - Drug Profile 199
RG-7596 - Drug Profile 200
IMGN-529 - Drug Profile 202
ABT-199 - Drug Profile 203
ROR-1 Inhibitors Small Molecule - Drug Profile 206
rituximab biosimilar - Drug Profile 207
cholecalciferol - Drug Profile 208
GS-9973 - Drug Profile 209
KPT-330 - Drug Profile 210
Anti-CD38 - Drug Profile 212
TGR-1202 - Drug Profile 213
rituximab biosimilar - Drug Profile 214
IGN-786 - Drug Profile 215
Drug Targeting L-Selectin - Drug Profile 216
PRT-060318 - Drug Profile 217
OP-449 Backup - Drug Profile 218
Ritonavir Analogs - Drug Profile 219
OP-449 - Drug Profile 220
Monoclonal Antibodiy Targeting ROR-1 - Drug Profile 222
ROR-1 Peptide Vaccine - Drug Profile 223
Ethacrynic Acid Derivatives - Drug Profile 224
rituximab biosimilar - Drug Profile 225
GNR-022 - Drug Profile 226
ROR-1 Antibodies - Drug Profile 227
MSK-777 - Drug Profile 228
FB-811 - Drug Profile 230
rituximab biosimilar - Drug Profile 231
LDC-2636 - Drug Profile 232
PBS-1086 - Drug Profile 233
HCQ/CLB-Loaded Anti-CD20 Antibody - Drug Profile 235
Drug For Chronic Lymphocytic Leukemia - Drug Profile 236
hA19 Antibody - Drug Profile 237
OSU-2S - Drug Profile 238
Anti-CD22 Chimeric Antigen Receptor Expressing T-Cells - Drug Profile 239
HMPL-523 - Drug Profile 241
KAN-0439365 - Drug Profile 242
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Drug Profile Updates 243
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Discontinued Products 303
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Dormant Products 304
Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 306
Featured News & Press Releases 306

Appendix 314
Methodology 314
Coverage 314
Secondary Research 314
Primary Research 314
Expert Panel Validation 314
Contact Us 315
Disclaimer 315

List of Table


Number of Products Under Development for Chronic Lymphocytic Leukemia (CLL), H2 2013 18
Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2013 19
Number of Products under Development by Companies, H2 2013 21
Number of Products under Development by Companies, H2 2013 (Contd..1) 22
Number of Products under Development by Companies, H2 2013 (Contd..2) 23
Number of Products under Development by Companies, H2 2013 (Contd..3) 24
Number of Products under Development by Companies, H2 2013 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H2 2013 27
Comparative Analysis by Late Stage Development, H2 2013 28
Comparative Analysis by Mid Clinical Stage Development, H2 2013 29
Comparative Analysis by Early Clinical Stage Development, H2 2013 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 31
Products under Development by Companies, H2 2013 32
Products under Development by Companies, H2 2013 (Contd..2) 33
Products under Development by Companies, H2 2013 (Contd..3) 34
Products under Development by Companies, H2 2013 (Contd..4) 35
Products under Development by Companies, H2 2013 (Contd..5) 36
Products under Investigation by Universities/Institutes, H2 2013 37
Bristol-Myers Squibb Company, H2 2013 38
F. Hoffmann-La Roche Ltd., H2 2013 39
Amgen Inc., H2 2013 40
Sanofi-Aventis, H2 2013 41
Viralytics Ltd., H2 2013 42
GlaxoSmithKline plc, H2 2013 43
Genentech, Inc., H2 2013 44
MedImmune LLC, H2 2013 45
Gilead Sciences, Inc., H2 2013 46
Daiichi Sankyo Company, Ltd, H2 2013 47
Merck & Co., Inc., H2 2013 48
Emergent BioSolutions Inc., H2 2013 49
Lentigen Corporation, H2 2013 50
Infinity Pharmaceuticals, Inc., H2 2013 51
Amorfix Life Sciences Ltd., H2 2013 52
Celltrion, Inc., H2 2013 53
Novartis AG, H2 2013 54
Astellas Pharma Inc., H2 2013 55
Gedeon Richter Plc., H2 2013 56
ImmunoGen, Inc., H2 2013 57
SuperGen, Inc., H2 2013 58
Genmab A/S, H2 2013 59
Cyclacel Pharmaceuticals Inc., H2 2013 60
Celgene Corporation, H2 2013 61
Onyx Pharmaceuticals, Inc., H2 2013 62
Bayer AG, H2 2013 63
Incyte Corporation, H2 2013 64
Merck KGaA, H2 2013 65
4SC AG, H2 2013 66
IMMUNOMEDICS, INC, H2 2013 67
MethylGene Inc, H2 2013 68
Portola Pharmaceuticals, Inc., H2 2013 69
Mundipharma International Limited, H2 2013 70
MorphoSys AG, H2 2013 71
Panacea Biotec Limited, H2 2013 72
Simcere Pharmaceutical Group, H2 2013 73
Hybrigenics S.A., H2 2013 74
Spectrum Pharmaceuticals, Inc., H2 2013 75
Memgen, LLC., H2 2013 76
Hutchison MediPharma Limited, H2 2013 77
Arno Therapeutics, Inc., H2 2013 78
Semafore Pharmaceuticals, Inc., H2 2013 79
Ferrer Internacional S.A., H2 2013 80
Onconova Therapeutics, Inc, H2 2013 81
Tragara Pharmaceuticals, Inc., H2 2013 82
KaloBios Pharmaceuticals, Inc., H2 2013 83
Aprea AB., H2 2013 84
Cylene Pharmaceuticals, Inc., H2 2013 85
Biothera, H2 2013 86
Profectus BioSciences, Inc., H2 2013 87
LFB Biotechnologies, S.A.S.U., H2 2013 88
KAEL-GemVax, H2 2013 89
Bio Sidus S.A., H2 2013 90
Assessment by Monotherapy Products, H2 2013 91
Assessment by Combination Products, H2 2013 92
Assessment by Stage and Route of Administration, H2 2013 94
Assessment by Stage and Molecule Type, H2 2013 97
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Drug Profile Updates 249
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Discontinued Products 309
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Dormant Products 310
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Dormant Products (Contd..2) 311

List of Chart


Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2013 18
Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2013 19
Products under Development by Companies, H2 2013 20
Products under Investigation by Universities/Institutes, H2 2013 26
Late Stage Products, H2 2013 28
Mid Clinical Stage Products, H2 2013 29
Early Clinical Stage Products, H2 2013 30
Discovery and Pre-Clinical Stage Products, H2 2013 31
Assessment by Monotherapy Products, H2 2013 91
Assessment by Combination Products, H2 2013 92
Assessment by Route of Administration, H2 2013 93
Assessment by Stage and Route of Administration, H2 2013 94
Assessment by Molecule Type, H2 2013 95
Assessment by Stage and Molecule Type, H2 2013 96

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *